Furthermore, the homologous delivery of the chemotherapeutic doxorubicin (DOX) to breast cancer was achieved using CRISPR/Cas9-edited Pd-l1KO TDEV-fusogenic anthracycline liposomes with a high drug encapsulation efficiency (97%) to enhance the immunogenic response and promote PD-L1 overexpression in the tumor. This evidence concerns the gene CD274 and neoplasm.